CRF Health
announced that the company has recently completed the ePRO vendor certification program for use of the
EXA
cerbations of
C
hronic Pulmonary Disease
T
ool (EXACT). The EXACT is a patient-reported outcome (PRO) measure designed to standardize the method for evaluating the frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) in U.S., as well as international based studies and clinical trials. Developed by
United BioSource Corporation
(UBC) through a multi-sponsor consortium approach involving input from clinical and methodological advisors and involvement of the U.S. Food and Drug Administration (FDA), the EXACT is a standardized tool for measuring exacerbations of COPD.
CRF Health has achieved certification for two devices currently in use with many ongoing projects; the HTC® HD2 and the HTC® Touch 2, which both use the Windows® Mobile operating system. “This certification allows CRF Health to meet the needs of our client base with regard to using the EXACT measure in their respiratory clinical studies, while giving our sponsor-clients confidence that the data collected via CRF Health’s ePRO solutions will be captured in a consistent and proven manner,” stated John Jordan, Senior VP of eClinical Technology for CRF Health.
When collecting EXACT data, clients have the option of a smaller screen device (HTC® Touch 2) or a larger screen (HTC® HD2), depending on the design of the clinical study and the clients’ preferences.
“We are pleased to certify CRF Health on the electronic delivery of the EXACT and to continue our work with them in the use of the EXACT and other PROs in all types of clinical studies,” said Sonya Eremenco, ePRO Manager at United BioSource Corporation and EXACT Certification Program Manager.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.